Clinical importance of discordance in hormone receptor and HER2/NEU status after neoadjuvant chemotherapy in breast cancer

View/ Open
Access
info:eu-repo/semantics/openAccessDate
2014Author
Öven Ustaalioğlu, Bala BaşakAker Vardar, Fügen
Bilici, Ahmet
Gürleyik, Günay
Erkol, Burçak
Kefeli, Umut
Metadata
Show full item recordCitation
Öven Ustaalioğlu, B. B., Aker Vardar, F., Bilici, A., Gürleyik, G., Erkol, B. ve Kefeli, U. (2014). Clinical importance of discordance in hormone receptor and HER2/NEU status after neoadjuvant chemotherapy in breast cancer. 39th ESMO Congress (ESMO). Madrid, Spain, September 26-30, 2014. https://doi.org/10.1093/annonc/mdu328.5Abstract
Aim: Neoadjuvant chemotherapy (NAC) is used longer for both locally advanced breast cancer and early stage to increase breast conservation. Discordance of the hormone receptor (HR) status was reported to be 8-33% of the breast cancer after NAC. The aim of this study was to compare the HR and HER2/neu status between core needle biopsy (CNB) and residual tumour after surgery of breast cancer treated with NAC and also to evaluate effect of discordance and other clinicopathological factors on survival.
WoS Q Kategorisi
Q1Source
39th ESMO Congress (ESMO)Volume
25Issue
Supplement: 4Collections
- Bildiri Koleksiyonu [485]
- WoS İndeksli Yayınlar Koleksiyonu [5978]